Table 5.
The clinical characteristics of the patients ≤ 19 years old suffering from carditis after COVID-19 vaccination
| Patient characteristics (n = 301) | Mean/number | Standard deivation/% |
|---|---|---|
| Patient demographics | ||
| Age (year) | 15.90 | 1.52 |
| Male | 281 | 93.36% |
| Clinical diagnosis | ||
| Total carditis | 301 | 100.00% |
| Total myocarditis | 240 | 79.73% |
| Total pericarditis | 5 | 1.66% |
| Unclassified | 56 | 18.60% |
| Subgroup | ||
| Carditis after first dose | 38 | 12.62% |
| Carditis after second dose | 263 | 87.38% |
| Pericarditis after first dose | 3 | 60.00% |
| Pericarditis after second dose | 2 | 40.00% |
| Myocarditis after first dose | 30 | 12.50% |
| Myocarditis after second dose | 210 | 87.50% |
| Proportion of vaccine types | ||
| BNT162b2 | 339 | 79.39% |
| mRNA-1273 | 85 | 19.91% |
| Ad26.COV2.S | 1 | 0.23% |
| Unknown | 2 | 0.47% |
| Admission | ||
| Length of stay (days) | 3.905 | 1.75 |
| Intensive care unit | 53 | 20.31 |
| Resolution | 298 | 99.00% |
| Clinical manifestation | ||
| Chest pain | 293 | 97.34% |
| Fever | 113 | 37.54% |
| Shortness of breath | 64 | 21.26% |
| Myalgia | 51 | 16.94% |
| Headache | 47 | 15.61% |
| Nausea and vomiting | 31 | 10.30% |
| Palpitations | 8 | 2.66% |
| Laboratory results | ||
| Troponin (ng/mL) | 924.32 | 2017.01 |
| Median (Q1 to Q3) | 9.62 (5.40–828.09) | – |
| Min; max | 0.03; 7368.45 | – |
| C-reactive protein level (mg/mL) | 25.89 | 44.31 |
| Median (Q1–Q3) | 7.58 (4.06–24.70) | |
| Min; max | 0.57; 174 | |
| Treatment | ||
| Treatment received | 261 | 86.71% |
| NSAIDs | 226 | 86.59% |
| Steroids | 50 | 19.16% |
| Intravenous immunoglobulins | 57 | 21.84% |
| Angiotensin-converting enzyme (ACE) inhibitors | 2 | 0.77% |
| Colchicine | 24 | 9.20% |